Intracranial hemorrhages represent serious neurologic emergencies, whose diagnosis and treatment must be carried out rapidly and decisively. Their diagnosis, categorization, and appropriate treatment allocation can be easily guided by current imaging techniques. Although computed tomography (CT) has traditionally been considered the imaging modality of choice in the management of these patients, recent technologic advances have placed magnetic resonance imaging in an advantageous position to become a very important diagnostic tool, in some cases likely to replace CT.
Relationship disclosure: Dr Gomez has received personal compensation for activities with Alsius Corporation, Boston Scientific Corporation, Bristol-Myers Squibb Company, Cordis Corporation, Guidant Corporation, Sanofi-Aventis Pharmaceuticals, Inc., WL Gore, and Accumetrics as a consultant and scientific advisory board member. Dr Gomez has received research support from Abbott Laboratories, Inc., Alsius Corporation, AstraZeneca Pharmaceuticals, Bayer Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, Guidant Corporation, Parke-Davis, and Sanofi-Aventis Pharmaceuticals, Inc.
Unlabeled Use of Products/Investigational Use Disclosure: Dr Gomez has nothing to disclose.